Crescent Biopharma (C68) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

C68 Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Crescent

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

C68 Stock 12 Month Forecast

Average Price Target

€27.46

▲(100.47% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Crescent Biopharma in the last 3 months. The average price target is €27.46 with a high forecast of €32.10 and a low forecast of €24.08. The average price target represents a 100.47% change from the last price of €13.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","20":"€20","33":"€33","13.5":"€13.5","26.5":"€26.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.1004674,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€32.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.46373322,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.07535055,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€24.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13.5,20,26.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.638497492307692,15.176994984615384,16.715492476923075,18.25398996923077,19.79248746153846,21.330984953846155,22.869482446153846,24.407979938461537,25.946477430769228,27.48497492307692,29.02347241538461,30.56196990769231,{"y":32.1004674,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.281825632307692,14.463651264615384,15.645476896923078,16.82730252923077,18.009128161538463,19.190953793846155,20.372779426153848,21.55460505846154,22.736430690769232,23.918256323076925,25.100081955384617,26.28190758769231,{"y":27.46373322,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.1,13.02118081153846,13.942361623076923,14.863542434615384,15.784723246153845,16.705904057692308,17.62708486923077,18.54826568076923,19.469446492307693,20.390627303846152,21.311808115384615,22.232988926923078,23.15416973846154,{"y":24.07535055,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.174,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€32.10

Average Price Target€27.46

Lowest Price Target€24.08

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Willey

Stifel Nicolaus

€24.97

Buy

82.24%

Upside

Reiterated

10/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Biren Amin

Piper Sandler

€31.21

Buy

127.80%

Upside

Reiterated

10/16/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK), Crescent Biopharma (NASDAQ: CBIO) and Glaukos (NYSE: GKOS)

Mitchell Kapoor

H.C. Wainwright

€32.1

Buy

134.31%

Upside

Upgraded

10/06/26

Crescent Biopharma upgraded to Buy from Neutral at H.C. WainwrightCrescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright

Charles Zhu

LifeSci Capital

€24.97

Buy

82.24%

Upside

Reiterated

10/05/26

Analysts' Top Healthcare Picks: Novartis (NVS), Crescent Biopharma (CBIO)

Robert Driscoll

Wedbush

€24.08

Buy

75.73%

Upside

Reiterated

09/14/26

Wedbush Remains a Buy on Crescent Biopharma (CBIO)

Bradley Canino

Guggenheim

€31.21

Buy

127.80%

Upside

Reiterated

04/29/26

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Cytokinetics (NASDAQ: CYTK) and Crescent Biopharma (NASDAQ: CBIO)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

04/29/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Crescent Biopharma (NASDAQ: CBIO) and Guardant Health (NASDAQ: GH)

Akash Tewari

Jefferies

€31.21

Buy

127.80%

Upside

Reiterated

12/05/25

Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Willey

Stifel Nicolaus

€24.97

Buy

82.24%

Upside

Reiterated

10/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Biren Amin

Piper Sandler

€31.21

Buy

127.80%

Upside

Reiterated

10/16/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK), Crescent Biopharma (NASDAQ: CBIO) and Glaukos (NYSE: GKOS)

Mitchell Kapoor

H.C. Wainwright

€32.1

Buy

134.31%

Upside

Upgraded

10/06/26

Crescent Biopharma upgraded to Buy from Neutral at H.C. WainwrightCrescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright

Charles Zhu

LifeSci Capital

€24.97

Buy

82.24%

Upside

Reiterated

10/05/26

Analysts' Top Healthcare Picks: Novartis (NVS), Crescent Biopharma (CBIO)

Robert Driscoll

Wedbush

€24.08

Buy

75.73%

Upside

Reiterated

09/14/26

Wedbush Remains a Buy on Crescent Biopharma (CBIO)

Bradley Canino

Guggenheim

€31.21

Buy

127.80%

Upside

Reiterated

04/29/26

Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Cytokinetics (NASDAQ: CYTK) and Crescent Biopharma (NASDAQ: CBIO)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

04/29/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Crescent Biopharma (NASDAQ: CBIO) and Guardant Health (NASDAQ: GH)

Akash Tewari

Jefferies

€31.21

Buy

127.80%

Upside

Reiterated

12/05/25

Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KNSAKiniksa Pharmaceuticals

OMCLOmnicell

AXGNAxoGen

ONCBeOne Medicines

AHCOAdaptHealth

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crescent Biopharma

3 Months

Biren AminPiper Sandler

Success Rate

5/12 ratings generated profit

Average Return

+3.82%

Copying Biren Amin's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +3.82% per trade.

1 Year

Biren AminPiper Sandler

Success Rate

7/12 ratings generated profit

Average Return

+12.13%

Copying Biren Amin's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +12.13% per trade.

2 Years

Biren AminPiper Sandler

Success Rate

7/12 ratings generated profit

Average Return

+13.21%

Copying Biren Amin's trades and holding each position for 2 Years would result in 58.33% of your transactions generating a profit, with an average return of +13.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

C68 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, C68 has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. C68 average Analyst price target in the past 3 months is 27.46.

Each month's total comprises the sum of three months' worth of ratings.

C68 Financial Forecast

C68 Earnings Forecast

Next quarter’s earnings estimate for C68 is -€0.58 with a range of -€0.73 to -€0.45. The previous quarter’s EPS was -€0.63. C68 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year C68 has Performed in-line its overall industry.

C68 Sales Forecast

Next quarter’s sales forecast for C68 is €305.91K with a range of €0.00 to €2.14M. The previous quarter’s sales results were €0.00. C68 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year C68 has Performed in-line its overall industry.

C68 Stock Forecast FAQ

What is DE:C68’s average 12-month price target, according to analysts?

Based on analyst ratings, Crescent Biopharma’s 12-month average price target is 27.46.

What is DE:C68’s upside potential, based on the analysts’ average price target?

Crescent Biopharma has 100.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Crescent Biopharma a Buy, Sell or Hold?

Crescent Biopharma has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Crescent Biopharma’s share price target?

The average share price target for Crescent Biopharma is 27.46. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €32.10 ,and the lowest forecast is €24.08. The average share price target represents 100.47% Increase from the current price of €13.7.

What do analysts say about Crescent Biopharma?

Crescent Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Crescent Biopharma?

To buy shares of DE:C68, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Crescent Biopharma (C68) Stock Forecast & Price Target

C68 Analyst Ratings

C68 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crescent Biopharma

C68 Analyst Recommendation Trends

C68 Financial Forecast

C68 Earnings Forecast

C68 Sales Forecast

C68 Stock Forecast FAQ

Detailed List of Analyst Forecasts